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Abstract: Opioid receptors are found in the Central Nervous System (CNS) and are classified as mu (µ), kappa
(6), delta (*) and sigma (F) opioid receptors. Opioid receptors belong to the large family of G Protein Coupled
Receptors (GPCRs), and have diverse and important physiological roles. The aim of the present review is to
discuss the roles played by opioid receptors, their agonists and antagonists in health and disease conditions.
Opioid receptors are not uniformly distributed in the CNS and are found in areas concerned with pain, with the
highest concentration in the cerebral cortex, followed by the amygdala, septum, thalamus, hypothalamus,
midbrain and spinal cord. Activated delta opioid receptors are coupled to Gi1 while activated mu opioid
receptors are coupled to Gi3 in neuroblastoma cells. Mu opioid receptors are activated by mu receptor agonists
and are coupled through the G"i1 and G"oA. Both mu and kappa opioid receptors are coupled via both Gi and
Gz and opioid receptors are important targets for thousands of pharmacological agents. GPCRs typically require
activation by agonists for their signalling activity to be initiated but some of the GPCRs may display basal or
spontaneous signalling activity in the absence of an agonist. The stimulation of these receptors triggers
analgesic effects and affects the function of the nervous system, gastrointestinal tract and other body systems.
Hundreds of analogs of opioid peptides have been synthesized in an effort to make the compounds more active,
selective, and resistant to biodegradation than the endogenous ligands. All these modifications resulted in
obtaining very selective agonists and antagonists with high affinity at mu-, delta-, and kappa-opioid receptors,
which are useful in further studies on the pharmacology of opioid receptors in a mammalian organism. 
Key words: Delta opioid, G-protein coupled receptors, 6-Opioid, µ-Opioid, opioid agonists, opioid
antagonists, opioid receptors
INTRODUCTION
The term opioid refers to any natural or synthetic
drugs that have morphine-like activity. They are classified
as natural, semi-synthetic and synthetic opioids. Examples
of natural opioids are morphine, codeine noscopine; semi-
synthetic are heroin, oxymorphone and hydromorphone,
while the synthetic opioids are methadone, morphinians
and benzamorphans (Piestrzeniewicz et al., 2006). Opioid
receptors are found in the Central Nervous System (CNS)
and are classified as mu (µ), kappa (6), delta (*) and
sigma (F) opioid receptors. Opioid receptors are not
uniformly distributed in the CNS but are found in areas
concerned with pain receptors, with the highest
concentration in the cerebral cortex, followed by the
amygdala, septum, thalamus, hypothalamus, midbrain and
spinal cord (Raynor et al., 1996; Chaturvedi et al., 2000).
The mu receptor has been shown to be high in areas of
pain perception and in the medulla, especially in the area
for respiration (Reisine and Bell, 1993; Reisine and
Brownstein,    1994;    Massotte   and   Kieffer,  1998;
Hasbi et al., 2000). 
The  opioid  receptors  (mu,  delta,  and kappa)
belong  to  the  large  family  of  GPCRs  and  have
diverse  and  important  physiological roles
(Piestrzeniewicz et al., 2006; Rhim and Miller, 1994).
Laugwitz et al. (1993) have shown that activated delta
opioid receptors are coupled to Gi1 while activated mu
opioid receptors are coupled to Gi3 in neuroblastoma cells
(SH-SY5Y). Mu opioid receptors have been shown to be
activated by mu receptor agonists and are coupled through
the G"i1 and G"oA in human embryonic kidney (HEK
239) cells (Saidak et al., 2006). Tso and Wong (2000),
have shown that both mu and kappa opioid receptors are
coupled via both Gi and Gz in HEK 239 cells. The opioid
receptors are important targets for thousands of
pharmacological    agents    (Hasbi    et    al.,   2000;
Wang et al., 2007). The stimulation of these receptors
triggers analgesic effects and affects the function of the
nervous  system,  gastrointestinal  tract  and  other  body
Br. J. Pharmacol. Toxicol., 2(2): 84-91, 2011
85
systems (Piestrzeniewicz  et  al., 2006). The discovery of
opioid peptides (including delta-selective enkephalins,
kappa-selective dynorphins, and mu-selective
endomorphins), which are endogenous ligands of opioid
receptors, initiated their structure-activity relationship
studies (Fichna et al., 2006).
Piestrzeniewicz et al. (2006) have shown that in the
last 30 years, hundreds of analogs of opioid peptides have
been synthesized in an effort to make the compounds
more active, selective, and resistant to biodegradation
than the endogenous ligands. Different unnatural amino
acids, as well as cyclisation procedures, leading to
conformationally restricted analogs, were employed. All
these modifications resulted in obtaining very selective
agonists and antagonists with high affinity at mu-, delta-,
and kappa-opioid receptors, which are extremely useful
tools   in  further  studies  on  the  pharmacology  of
opioid receptors  in  a  mammalian  organism
(Piestrzeniewicz et al., 2006; Xiong et al., 2007). GPCRs
typically   require   activation   or   stimulation   by
agonists for their signalling activity to be initiated but
Wang et al. (2007), have shown that some of the GPCRs
display basal or spontaneous signalling activity in the
absence of an agonist. This basal or spontaneous
signalling activity is also called constitutive activity
(Wang et al., 2007; Piiper and Zeuzem, 2004).
As mentioned, opioids exert their biological activity
through the activation by GPCRs, and their effects can be
blocked by receptor antagonists. Opioid antagonists with
different inverse agonist properties have different effects
in precipitating withdrawal in acute morphine dependent
mice, and constitutive opioid receptor activation is
critically involved in acute opioid withdrawal (Freye and
Levy, 2005; Wang et al., 2007; Xiong et al., 2007). It has
been shown that the pharmacological properties and
activities of the three opioid receptor classes are distinct
and can be clearly differentiated (Raynor et al., 1996).
Opioid receptors have high affinity for both agonists and
antagonists. DAMGO and its antagonists do not bind to
delta or kappa receptors, and morphine and its derivatives
are much less potent at the delta or kappa receptors. All
the three opioid receptors are sensitive to the antagonist
naloxone  (Raynor  et  al., 1996; Raynor et al., 1994;
Wang et al., 2007). The aim of the present review is to
discuss the roles played by opioid receptors, their agonists
and antagonists in health and disease conditions
Uses  of  opioids:  Opioids  have  long  been  used  to
treat   acute   pain,   such   as   post-operative  pain
(Raynor et al., 1994). They are commonly prescribed, and
used, because of their effective analgesic properties.
Studies have shown that properly managed medical use of
opioid analgesic compounds is safe and rarely causes
addiction. Taken exactly as prescribed, opioids can be
used to manage pain effectively. They have also been
found to be invaluable in palliative care to alleviate the
severe, chronic and disabling pain of terminal conditions
such as cancer and AIDS (Doyle et al., 2004). Contrary to
popular belief, high doses are not required to control the
pain of advanced or end-stage disease. In recent years
there has been an increased use of opioids in the
management of non-malignant chronic pain. This practice
has grown from over 30 years experience in palliative
care of long-term use of strong opioids, which has shown
that dependence is rare when the drug is being used for
pain relief (Doyle et al., 2004)
In addition to analgesia, clinical uses of opioids
include codeine and hydrocodone for cough, natural
opioids for diarrhoea, oxymorphone for anxiety due to
shortness of breath and methadone and buprenorphine for
heroin detoxification and maintenance programs during
heroin replacement therapy (Eap et al., 1999, 2002).
Despite the fact that opioids have been extensively
reported to have psychological benefits, they are never
officially prescribed to treat psychological illnesses, even
in circumstances where researchers have reported opioids
to be especially effective for example in the treatment of
senile dementia, geriatric depression, and psychological
distress due to chemotherapy or terminal diagnosis
(Berridge, 2006).
Doyle et al. (2004) have shown that opioids are used
to treat pain of moderate or greater severity, irrespective
of the underlying pathophysiological mechanism.
Morphine has been used to treat breathlessness of which
several mechanisms have been suggested for its action.
Codeine and loperamide are the most widely used opioids
for diarrhoea. Loperamide has the advantage of acting
only on the gut, since very little is absorbed and topical
morphine in an aqueous gel can be an effective agent for
treatment of painful wounds. Their use is based on the
discovery of activated opioid receptors in damaged tissue
(Doyle et al., 2004). Opioid medications can affect
regions of the brain, resulting in the initial euphoria that
many opioids produce. They can also produce drowsiness,
because constipation and depending upon the amount
taken, depress breathing. When taken as a large single
dose, opioids could cause severe respiratory depression or
death (Wang et al., 2007). 
Opioid receptor activation: Milligan (2004) has shown
that the opioid receptors form homomeric as well as
heteromeric receptor complexes. Opioid receptors are
capable of forming a heterodimer with each other and
certain non-opioid receptors, for example, mu with
alpha2a-adrenoceptors  (Devi,  2001).  This
heterodimerisation between opioid receptors has been
shown to result in changes in the pharmacology of the
receptors as well as changes in receptor coupling to
second messengers and trafficking (Corbett et al., 2006).
It has been shown that both mu and delta receptors
internalise   on   exposure   to  agonists,  whereas   kappa
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Table 1: Some agonists and antagonists of opioid receptor subtypes




enkephalin (DPDPE) SDM25N hydrochloride
[D-serine 2, O-Leu5]- Naltriben mesylate





ICI 204,448 (ICI) 7-benzylidenenaltrexone
ICI-199441hydrochloride (BNTX)
U-54494A hydrochloride  [3H]diprenorphine
BRL 52537- ([3H]DIP)
hydrochloride  GNTI dihydrochloride
Mu (D-Ala2-MePhe4, Gly-ol5) enkephalin (DAMGO) D-Phe-Cys-Tyr-D-Trp-Orn-Pen-Thr-NH2         
Morphine (CTOP)
Loperamide-hydrochloride  Naloxonazine Cyprodime hydrochloride
Endomorphin-1 H-D-Phe-Cys-Tyr-D-Trp-
Endomorphin-2 Arg-Thr-Pen-Thr-NH2. (CTAP)
receptors do not and when such dimers such as
delta/kappa dimers are formed, the trafficking properties
of the kappa receptor predominates, while the heterodimer
does not internalise on exposure to agonists of either
receptors (Corbett et al., 2006; Koch and Hollt, 2008).
Opioid receptor subtypes have been proposed largely on
the basis of radioligand binding studies and as such there
is little or no evidence for the presence of the different
genes encoding these subtypes but in some cases, receptor
heterodimerisation of opioid receptors has been proposed
as a possible explanation (Corbett et al., 2006). Table 1
shows some of the agonists and antagonists of the opioid
receptor subtypes. 
All of the opioid receptors are GPCRs and couple to
their cellular effectors primarily through Gi/Go proteins,
and thus the majority of opioid responses are pertussis
toxin-sensitive   (Milligan   and   Kostenis,   2006).
Corbett et al. (2006) have shown that the different
behaviours mediated by each of the receptor subtype in
the intact animal such as euphoria for mu and dysphoria
for kappa, result not from each type of receptor evoking
different cellular responses but from the different
anatomical distributions of each receptor (Corbett et al.,
2006). Although the predominant action of opioids in the
nervous system is inhibitory, in several brain regions such
as Periaqueductal Grey (PAG), important for supraspinal
analgesia or ventral tegmental area (VTA), for euphoria/
reward, opioids are excitatory (Corbett et al., 2006). It has
been shown that opioid-induced excitations are due, not
to a direct excitatory action of opioids, but to disinhibition
(Corbett et al., 2006). The apparent excitation of a neuron
by opioids is as a result of inhibition of the release of
inhibitory neurotransmitters such as Gamma Amino
Butyric Acid (GABA) from the interneurons into the cell
(Corbett et al., 2006).  
Opioids have been shown to act via receptors
interacting with heterotrimeric pertussis toxin (PTX)
sensitive G proteins. The mu-selective agonist, DAMGO,
and the delta-selective agonist, [D-Pen2,D-Pen5]-
enkephalin (DPDPE) stimulated  the incorporation of the
photo-reactive GTP analogue into proteins co-migrating
with the alpha subunits of Gi1, Gi2, Gi3, Go1, and Go2 in the
membranes of neuroblastoma SH-SY5Y cells while in the
membranes of PTX-treated cells, both agonists were
ineffective, because mu and delta opioid receptors appear
to discriminate between PTX-sensitive G proteins which
lead  to  activation  of distinct G protein subtypes
(Laugwitz et al., 1993). Subtype-specific immuno-
precipitation of G protein alpha subunits photo-labelled in
the absence or presence of agonists revealed profound
differences between mu and delta opioid receptors in
coupling to PTX-sensitive G proteins (Milligan, 2004).
Opioid inhibition of neuronal excitability resulting in
the down-regulation of pain occurs largely by activation
of potassium channels in the plasma membrane (Samways
and Henderson, 2006). Opioid receptors are now known
to activate a variety of potassium channels, including G-
protein-activated inwardly rectifying (GIRK), calcium-
activated inwardly rectifying, dendrotoxin-sensitive and
M-type channels (Williams et al., 2001). Opioid receptors
have been shown to inhibit high threshold voltage-
activated calcium channels, like other members of the
Gi/Go-coupled receptor family such as cannabinoid (CB1)
receptors (Corbett et al., 2006). In some cell types, such
as neuronal cells, opioid receptor activation can also cause
an elevation of the free calcium concentration inside cells
by releasing calcium from intracellular stores or by
enhancing calcium entry by a dihydropyridine-sensitive
mechanism (Samways and Henderson, 2006). It has been
shown that the activation of opioid receptors stimulates a
variety of intracellular signalling mechanisms including
activation of inwardly rectifying potassium channels, and
inhibition  of  both  voltage-operated N-type Ca2+
channels   and  adenylyl  cyclase  activity  (Samways and
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Henderson, 2006). It is now apparent that like many other
Gi/Go-coupled receptors, opioid receptor activation can
significantly elevate intracellular free Ca2+, although the
mechanism underlying this phenomenon is not well
understood (Samways and Henderson, 2006). In some
cases opioid receptor activation alone appears to elevate
intracellular Ca2+, but in many cases it requires
concomitant activation of Gq-coupled receptors, which
themselves stimulate Ca2+ release from intracellular stores
via the inositol phosphate pathway (Samways and
Henderson, 2006).
Opioid receptors, like other Gi/Go-coupled receptors,
inhibit adenylyl cyclase resulting in a fall in intracellular
cAMP (Corbett et al., 2006). Williams et al., (2001), have
shown that in primary afferent neurons, opioid receptors
activate and regulate multiple second messenger pathways
associated with effector coupling, receptor trafficking,
nuclear signalling and modulates the activation of
hyperpolarization-activated cation channels. In opioid
withdrawal, cAMP levels are elevated and enhanced
protein kinase A (PKA) activity increases
neurotransmitter release (Corbett et al., 2006). Opioid
receptors, like many other GPCRs, cycle to and from the
plasma membrane from intracellular compartments
(Corbett et al., 2006). This cycling is caused by agonist
activation of the receptors which results in the cycling of
the receptors to the plasma membrane in response to
various stimuli (Williams et al., 2001). The generally
accepted mechanism underlying mu and delta receptor
desensitization, is that agonist-activated receptors on the
plasma membrane are phosphorylated by G-protein-
coupled receptor kinases (GRKs), which facilitates
arrestin binding and prevents the receptor from coupling
to G-proteins (Bailey and Connor, 2005). Arrestin-bound
receptors are rapidly concentrated in clathrin-coated pits
and undergo dynamin-dependent internalisation into early
endosomes (Corbett et al., 2006). Delta receptors are
trafficked into lysosomes and are down-regulated,
whereas mu receptors are trafficked into endosomes,
where   they   are   dephosphorylated   and    recycled
back to the plasma membrane in a re-sensitised state
(Corbett et al., 2006). Thus, for mu receptor,
internalisation can be considered to be involved in re-
sensitisation, but not in desensitisation and there is
evidence that different C-terminus splice variants of the
mu receptor re-sensitise at different rates while the kappa
receptors do not appear to internalise in response to
agonist activation (Corbett et al., 2006).
Chakrabarti et al. (1995) have suggested that
different G-proteins can be activated with different
potencies by mu receptor agonists in Chinese-hamster
ovary cell membranes, which agrees with studies on delta-
and kappa-opioid receptors, suggesting that commonly
used   agonists   of   these   receptors  can  activate
multiple  G-protein  subtypes  with similar potency
(Burford et al., 2000). Carter and Medzihradsky (1993)
have shown that mu-selective agonist, DAMGO inhibited
cAMP formation in membranes of human neuroblastoma
cells (SH-SY5Y), differentiated with retinoic acid.
Antibodies to Gi alpha 1, 2 or Gi alpha 3 reduced the mu-
opioid signal insignificantly and inhibition of adenylyl
cyclase by the delta-opioid agonist (DPDPE) was very
sensitive to the Gi alpha 1, 2 antibodies (Carter and
Medzihradsky, 1993). 
Interaction of opioids and cannabinoids: Opioids and
cannabinoids are among the most widely consumed drugs
of abuse in the world (Manzanares et al., 1999; Smart and
Ogborne, 2000). Both drugs have been shown to share
some   pharmacological   properties   including
antinociception, hypothermia, sedation, hypotension,
inhibition of both intestinal motility and locomotor
activity (Manzanares et al., 1999). It has been reported
that there is a cross-tolerance or mutual potentiation of
these pharmacological effects. These phenomena have
supported the possible existence of functional linkage in
the mechanisms of action of both drugs especially in
antinociception and drug addiction (Manzanares et al.,
1999; Manzanares et al., 2005). 
The cannabinoid and opioid compounds mimic
endogenous ligands and act through the GPCRs,
cannabinoid and opioid receptors (Felder and Glass, 1998;
Kieffer, 1995). It has been shown that chronic
administration of )9-THC increases opioid gene
expression while, acute administration of )9-THC
increases extracellular levels of endogenous enkephalins
in the nucleus accumbens of mice (Corchero et al., 1997;
Valverde et al., 2001). Some studies have also
demonstrated the existence of cross-tolerance between
opioid and cannabinoid agonists and such, morphine-
tolerant animals show decreased )9-THC antinociceptive
responses, whereas )9-THC-tolerant rodents show a
decrease in morphine antinociception (Thorat and
Bhargava, 1994; Ghozland et al., 2002). There is cross-
dependence between opioid and cannabinoid compounds
and opioid antagonist naloxone precipitated a withdrawal
syndrome in )9-THC-tolerant rats, whereas cannabinoid
antagonist SR171416A was able to precipitate abstinence
in morphine-dependent rats (Navarro et al., 1998;
Ghozland et al., 2002). The severity of opioid withdrawal
was reduced by the administration of )9-THC or
anandamide (Vela et al., 1995; Valverde et al., 2001). This
bidirectional cross-dependence was confirmed by using
knock-out mice and opioid dependence was reduced in
mice lacking the CB1 receptor whereas, cannabinoid
dependence was reduced in mice lacking the
preproenkephalin   gene   (Ledent   et   al.,  1999;
Valverde et al., 2000). 
Cannabinoids produce their rewarding effects by
stimulating mesolimbic dopaminergic transmission which
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has been shown to be a common substrate for the
rewarding   effects   of   other   substances  of abuse
(Tanda et al., 1997). The activation of mu-opioid
receptors could be involved in the bidirectional interaction
between the endogenous cannabinoid and opioid systems
in reward that extends to central mechanisms underlying
relapsing phenomena (Fattore et al., 2004). This is
because  the  endogenous  cannabinoid  system
participates  in  the  rewarding  effects  of opioids
(Ghozland et al., 2002), and both morphine self-
administration  and  place  preference are decreased in
mice lacking the CB1 receptors (Ledent et al., 1999;
Martin et al., 2000). The possible involvement of the
endogenous opioid system in the different motivational
responses induced by cannabinoids is not yet well
understood, however, GABAergic and corticotrophin-
releasing factor systems, have been suggested to be
involved in the anxiogenic responses induced by
cannabinoids  and  these  anxiogenic  behaviours could
have some influence in the dysphoric effects of
cannabinoids (Rodríguez de Fonseca et al., 1996;
Ghozland et al., 2002).
Ghozland et al. (2002), have shown that the
disruption of mu-, delta-, or kappa-opioid receptor gene
does not modify acute )9-THC responses while the
expression of )9-THC withdrawal, and the development
of )9-THC tolerance is only slightly altered in Kappa
Opioid Receptor (KOR) knockout mice. Both mu- and
kappa-opioid ligands have been reported to modulate
cannabinoid antinociception (Manzanares et al., 1999).
The )9-THC antinociception was blocked in mice by the
kappa-selective opioid antagonist norbinaltorphimine, and
by high doses of the non-selective opioid antagonist
naloxone (Smith et al., 1998; Ghozland et al., 2002). The
synergistic effects of morphine and )9-THC on
antinociception were also blocked by norbinaltorphimine,
a mu selective antagonist (Reche et al., 1996) and high
doses of opioid antagonists are usually required to block
)9-THC antinociception (Manzanares et al., 1999).
Laboratory reports have shown that kappa receptors could
contribute to the development of adaptive responses to
chronic )9-THC administration, in agreement with the
demonstration of cross-tolerance between )9-THC and
kappa-opioid agonists (Smith et al., 1994). 
A non-selective opioid antagonist naloxone,
precipitates an opioid-like withdrawal syndrome in
cannabinoid-dependent rodents while, the CB1
cannabinoid receptor antagonist SR 141716A, induces
withdrawal in morphine-dependent rats (Navarro et al.,
1998). This suggests that simultaneous activation of the
two endogenous systems could participate in both opioid
and cannabinoid dependence (Ghozland et al., 2002;
Manzanares et al., 2005). Pre-treatment with )9-THC and
anandamide, have been shown to decrease morphine
withdrawal (Valverde et al., 2001), and the morphine-
induced rewarding effects were suppressed in mice
deficient in CB1 cannabinoid receptors, suggesting a
bidirectional  influence  of  µ-opioid  and  CB1 receptors
on   reward   processes   (Ledent   et   al.,   1999;
Ghozland et al., 2002).
Ghozland et al. (2002), have proposed that the
opposing µ-opioid and 6-opioid receptor activities
mediate the dual euphoric-dysphoric effects of )9-THC
and a possible mechanism for this could be that
cannabinoid receptor activation modifies endogenous
opioid   peptide   levels  in  mesolimbic  areas,   that
would   in   turn,  modulate  dopaminergic  activity
(Viganò et al., 2005). The release of opioid peptides by
cannabinoids or endocannabinoids by opioids and their
interactions at the level of receptor and their signal
transduction mechanisms supports the finding of
increased  opioid  peptide  levels  in  the  hypothalamus
after cannabinoid treatment (Corchero et al., 1997;
Viganò et al., 2005). 
Cannabinoids and opioids can also interact at the
level of their signalling activities. This is because reports
have shown that both cannabinoid and opioid receptor
types  are  coupled to similar intracellular effectors via
Gi/o-proteins, modulating cAMP levels, K+ and Ca2+
channel activities, and MAP kinase phosphorylation
(Bouaboula  et  al.,  1995;  Fukuda  et  al., 1996;
Manzanares et al., 1999). Viganò et al. (2005) studied the
mechanism of cross-modulation between cannabinoid and
opioid systems for analgesia during acute and chronic
exposure. The result showed that acute co-administration
of ineffectual sub-analgesic doses of synthetic
cannabinoid CP-55,940 and morphine resulted in
significant antinociception whereas, in rats made tolerant
to CP-55,940, morphine challenge did not produce any
analgesic response. The result of Viganò et al. (2005)
study also showed alterations in the cAMP system, which
seem to mirror the behavioural responses, indicating that
the two systems may interact at the post receptor level
which might open-up new therapeutic opportunities for
relief of chronic pain through cannabinoid-opioid co-
administration.
CONCLUSION
Opioid receptors and their agonists have long been
involved in the treatment of acute pain such as post-
operative pain. They are generally prescribed and used
due to their effective analgesic properties and when
properly managed the medical use of opioid analgesic
compounds is safe and do not cause addiction. They are
found to be invaluable in palliative care to alleviate
severe, chronic and disabling pain of terminal conditions
such as cancer and AIDS. Opioid use has increased over
time in the management of non-malignant chronic pain
and clinical uses of opioids include for cough, diarrhoea,
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anxiety, heroin detoxification and maintenance programs
during heroin replacement therapy. Opioids have been
shown to be especially effective in the treatment of senile
dementia, geriatric depression, and psychological distress
due to chemo therapy or terminal diagnosis. Opioids
receptors and their agonists are used to treat pain of
moderate and greater severity, irrespective of the
underlying pathophysiological mechanism.
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